Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Incyte drug on TGA fast track

Posted 6 May 2021 AM

Incyte's first-in-class Pemazyre is the only new drug on a list of cancer therapies recently granted fast-track pathways by the TGA as other companies look to grow their franchises.

The TGA has granted Pemazyre a provisional approval determination, meaning the drug could be registered on the ARTG provisionally by the end of year with the regulator taking a median of 195 days to review applications on the pathway in the last half of 2020.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Could access probe be for nothing?
Significant industry participation but what outcome?
Approvals Action
Injectable antibiotic ticked
Fresenius Kabi adds to Gram-positive options